Clinical Trial Update: Study of Fampridine-SR Tablets in Multiple Sclerosis Patients [Phase 3]

View source ↗

Summary

A Phase 3 study of dalfampridine extended-release (Fampridine-SR) tablets in patients with multiple sclerosis has completed. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Fampridine-SR (fampridine)

Snippet

Sponsor: Acorda Therapeutics | Conditions: Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2011-04-14